FOSL1 and neoplasm: FOSL1 immunostaining was negative in 12/15 cases, whereas 3/15 (FTS5, FTS11, FTS12) showed equivocal weak nuclear immunoreactivity (1+) with a minor population of tumour cells demonstrating stronger (2+/3+) positivity (Figure 2E).